Life Sciences & Healthcare Venture Summit. Funding Healthcare & IT Media October 27, 2009

Similar documents
Mara H. Rogers, Partner Norton Rose Fulbright

FUNDS DATABASE SCOPE INCLUSION CRITERIA DATA HIGHLIGHTS

M&A Update 1H Proven. Focused. Trusted. Accounts Receivable Management Healthcare IT Revenue Cycle Management

How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners

Fall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE

IVC-MEITAR HIGH-TECH EXITS H1/ 2015 REPORT. IVC-Meitar 2014 Exits Report Prepared by IVC Research Center Ltd.

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update

Final Pitch Competition PROGRAM GUIDE. Wednesday, March 2, 2016 at HIMSS16 VENETIAN - PALAZZO - SANDS EXPO CENTER LEVEL 3 - LIDO 3104 LAS VEGAS, NV

Venture Capital Search Highlights

Management to Host Conference Call at 8:30 a.m. ET today

Venture Capital Report

Venture-Backed Exit Activity Shows Improved Signs of Life in Q1 2010

NOT FOR DISTRIBUTION IN THE USA,CANADA, JAPAN OR AUSTRALIA

Trends in Healthcare Investments and Exits 2018

Purvi B. Maniar Member of the Firm

Comprehensive Research Services

January Bob DeSutter Managing Director Co-Head of Health Care

Average M&A Deal Size at Highest Level Since 2004

MassMEDIC Annual Meeting

DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview

Strong Equity Support

Medtech Slowdown. Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year

VENTURE-BACKED IPO EXIT ACTIVITY MORE THAN DOUBLES IN Q WITH STRONGEST QUARTER FOR BIOTECH OFFERINGS SINCE 2000

Digital Health. Jiban Khuntia, PhD. Assistant Professor Business School University of Colorado Denver

2011 Angel Group Year in Review

VentureSource Europe -- 3Q 2014

2017 Summer Survey. Combined Report (Draft) January 17, 2018

Israel Venture Capital Investments Report Q3 2017

Co C m o pa p n a y n Pr P o r f o il i e l Nove v mb m e b r r

Life Sciences Outlook. Westchester County 2016

At the forefront of Abu Dhabi s economic diversification. August 2008

Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through

TENOR CAPITAL PARTNERS. ESOP Leveraged Buyout Specialist,

ALANCO TECHNOLOGIES INC

Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D.

The Great Convertible Note Debate What New Angels Need to Know

VentureSource U.S. -- 4Q 2013

MANAGING DIRECTOR 360 MADISON AVENUE NEW YORK, NY

Moving Ahead. Third-quarter Technology venture capital investment increased 33 percent yearover-year. percent quarter-over-quarter.

The Evolving Eco-system of the Medical Device Industry. An analysis prepared by MassDevice.com

Pharma - Biotech Collaborations: Optimizing Success, Minimizing Risk and Maintaining Alignment

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

CHINA MED DEVICE. China Medtech Will Continue Its Double Digit Growth in Years to Come

FINC915 Venture Lab Participating Firms: FALL 2010

HEALTHCARE ADVISORY SERVICES

SESSION 9A: SOURCES OF CAPITAL, VC FUND ECONOMICS

Omeros Raises More Than $63 Million in Financing

Life Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. New Jersey JLL Research

Commercialization Strategies that Work

Advised Mubadala Development Company PJSC in connection with the sale of interests in a ports operating company.

VALUATION TRENDS 18.8

Healthcare Focus. Trends in Capital Flows into Healthcare

About Us. Sterling Capital is a China centric boutique M&A firm with extensive on the ground China experience since 2003.

PRECISE MEDICAL Self-revealing case Handout #1

Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile

Mindray Medical International Limited (MR) - Medical Equipment - Deals and Alliances Profile

Venture Capital Report

Overview of Venture Equity

Finomics Business Conclave of XIMB, XUB

Collaborating with the Office of Technology Transfer

Venture Capital Report

Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Investor Presentation & Financial Highlights. November 2018

AMCo current. Medpace new in Sebia realised. Spire Healthcare partially realised. Healthcare. Sector insights. Our Healthcare portfolio in 2014

Driving profitable growth in Greater China. Andy Ho Chief Market Leader Greater China

The MoneyTree Report. Overview of Venture Capital Investments Third Quarter 2009

Agenda. Genesys Capital Partners. The Opportunity. Our Approach

Digital Health Funding and M&A

VENTURE-BACKED IPO EXIT ACTIVITY KEEPS MOMENTUM WITH BEST FULL YEAR FOR NEW LISTINGS SINCE 2007; THIRD CONSECUTIVE QUARTER FOR 20+ OFFERINGS SINCE

Financing Emerging Growth Companies

Venture Capital Report

ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

What s Hot? The M&A and Funding Landscape for Embedded Vision Companies

In all our work, we leverage our three fundamental strengths. Chairman & CEO. Managing Director. Representative Industries

Firm Overview. The firm includes 25 professionals, including 19 lawyers and 6 patent agents and technical specialists, of whom 10 hold Ph.D. degrees.

Life Sciences Outlook. New York City 2016

September 18, 2017 Special Called Meeting of the U. T. System Board of Regents - Meeting of the Board

Master Class : Excellence in Private Equity & Deal Structuring

executives are often viewed to better understand the merits of scientific over commercial solutions.

2013 venture capital trends summary

Patenting Strategies. The First Steps. Patenting Strategies / Bernhard Nussbaumer, 12/17/2009 1

Median Kliniken GmbH & Co. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Digital Health AI in Life Sciences

Venture Capital Report

Healthcare Products & Services Industry Update Q2 2017

TECH START-UP CONNECTING ACROSS GEOGRAPHIES

Generex Biotechnology Provides 2018 Year-End Summary & 2019 Plans

Fortis to acquire strategic stake in Parkway Holdings, Singapore

FINC915 Venture Lab Participating Firms: FALL 2009

Venture Capital Report

gellerbiopharm A healthcare investment banking division of Financial West Group, member FINRA/SIPC. Office (212) Web gellerbp.

HFMA Summer Conference

Dealdoc. Acquisition agreement for Gambro. Baxter International Gambro. Dec , Wildwood Ventures Ltd. All rights reserved.

Revenue of $100 million to $1 billion and EBITDA in excess of $20 million

Robert A. Greising Partner

Investor Presentation. August 2017 OTCQB: ZYXI

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond

Transcription:

Life Sciences & Healthcare Venture Summit Funding Healthcare & IT Media October 27, 2009

Emilio Ragosa Emilio Ragosa is a partner in Morgan Lewis's Business and Finance Practice. He focuses primarily on venture capital, securities offerings, mergers and acquisitions, and other corporate transactions. He represents both private and public technology and biotechnology companies, as well as venture capital firms and underwriters. Emilio also has handled numerous corporate transactions ranging from public and private mergers and acquisitions and private placements to public offerings. Prior to joining Morgan Lewis, Emilio was a junior partner with a prestigious national law firm. While in law school, he worked at the New York Stock Exchange; prior to law school, he was an intern with Merrill Lynch. Emilio is admitted to practice in New Jersey and New York.

Boston Millennia Partners Name of Fund Boston Millennia Partners Name of Contact Robert Jevon / robj@bmpvc.com Industry/Sector Full spectrum Healthcare Devices Focus (orthopedic, cardiovascular), later stage and specialty therapeutics, Health Information Technology Portfolio Fund size $400 Million - 22 active companies Deal Size First check $1-$5 million - can put up to $25 into a company Recent Deals Arthrosurface, CardioMEMS, MedAptus, and Collegium

Early Stage Partners Size: $100 Million under management Stage: Series A, Series B, Series C Investment: $1-5 million per investment Leadership: Lead 75% of our Portfolio deals Sector: Life Science, Technology, CleanTech Portfolio: Life Sciences CleanTech Technology

Health Enterprise Partners Name of Fund Health Enterprise Partners Name of Contact Bob Schulz General Partner 212-981-6923 / rschulz@hepfund.com Industry/Sector Healthcare services / Healthcare Focus Information Technology Particular focus on companies that sell to hospitals or health plans Prefer companies that are profitable or cash flow breakeven Portfolio Size Our current fund is $91M Deal Size Typically $5M, with ability to go up to $8 - $10M

Recent Deals Current Fund: Health Enterprise Partners (Cont d) OptimalIMX Radiology Services for hospitals Sheridan Healthcare Multi-specialty outsourced physician staffing for hospitals Behavioral Centers of America own/operates psych facilities SCIOinspire cost containment / revenue recovery / data analytics for health plans and employers Principle Pharmacy - manages closed door hospital pharmacies MobileMD hospital / physician office information exchange Prior Fund: Brim Healthcare Hospital management services Carefx Interoperability solutions for hospitals CareMedic Systems Revenue cycle management for hospitals CorSolutions Disease management for health plans and employers IPC The Hospitalist Company Hospitalist services for hospitals Passport Health Communications - Revenue cycle management for hospitals Emageon Enterprise wide image management software for hospitals Skylight Healthcare Systems Interactive patient communications system for hospitals Zonare Diagnostic untrasound device

HLM Venture Partners Name of Fund HLM Venture Partners Name of Contact Dan Galles - Partner dgalles@hlmvp.com Industry/Sector Healthcare VC, approx. 50% HCIT/HC Focus Services and 50% Medical Devices / Diagnostics Portfolio Size HCIT/HC Services typically minimum $4-5 million of revenues; Medical Devices clinical stage or later Deal Size $4-12 million per company over life of the company Recent Deals HCIT Medventive, Aperio, Phreesia; Medical Devices Valeritas, Transcend Medical, Interlace Medical

Milestone Venture Partners Name of Fund Milestone Venture Partners Name of Contact Todd Pietri 212-223-7400 / ttp@milestonevp.com Industry/Sector Early stage technology-enhanced services Focus (50% of portfolio in Healthcare IT & Healthcare Media) Portfolio Size We prefer post revenue companies ($500k+ in annual revenue) Deal Size Milestone invests $1m to $2m initially in financing rounds that are $5m or less. Recent Deals Integrichain (NJ) pharmaceutical data business. $1m investment in a $2 million round which closed Q2 2009 Vitals.com (NJ) Internet database company specializing in physician data. $1m investment in $4m round which closed Q3 2008

Milestone Venture Partners (Cont d) Recent Exits Medidata Solutions (NY) clinical electronic data capture software for pharmaceutical companies (IPO 6/25/2009 NASDAQ:MDSO, 35x in 7 years) Premise Development (CT) patient flow optimization software for hospitals (Eclipsys Corporation - NASDAQ: ECLP acquired Premise in December 2008, 2.5x in 20 months).